TCL Archive Von Eschenbach takes leave of absence from NCI, resigns from C-Change board. Acting FDA commissioner’s drug approval strategy rooted in unproven science. Von Eschenbach told NCI deputies he might drop in on meetings. Who’s really in charge? October 7, 2005
TCL Archive Cooperative Group Competing Renewals May Be Funded Only at 70-80% Of Amounts Recommended By CCIRC January 2, 1981
TCL Archive O’Neill Account, Kennedy Hearing, Create Climate On Capitol Hill for Increasing Cancer Funding May 3, 1991
